The Food and Drug Administration’s approval of Madrigal Pharmaceuticals’ drug “Rezdiffra” marks a significant milestone in the treatment landscape for nonalcoholic steatohepatitis (NASH), a severe form of liver disease affecting millions of Americans. Rezdiffra, to be used alongside diet and exercise, targets patients with moderate-to-advanced liver scarring, offering hope where previously there was none. Given… Continue reading Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study… Continue reading Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

The CEO of WeightWatchers, Sima Sistani, circulated an internal memo to employees addressing concerns about the company’s financial stability amidst recent media coverage and a significant drop in stock value. The memo aimed to reassure employees about the company’s solid financial position and the growth of its clinical business, particularly related to countering the threat… Continue reading WeightWatchers CEO just sent an internal memo to employees as stock crashes, amid debt concerns, Oprah exit

The Food and Drug Administration (FDA) has granted approval for the first-ever treatment targeting a common and potentially fatal liver disease known as nonalcoholic steatohepatitis (NASH), a significant milestone in the medical field. Madrigal Pharmaceuticals, the company behind the drug, saw a surge in its stock price following the approval, indicating high investor confidence in… Continue reading FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease

— Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia. Appili’s Director of Non-Clinical Research, Dr. Carl Gelhaus, Ph.D., together with medical doctors from the United… Continue reading Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product. Bucillamine The Company is… Continue reading Revive Therapeutics Provides Corporate Update

In a surprising move, Eli Lilly announced that the Food and Drug Administration (FDA) has postponed its decision deadline for the approval of their experimental Alzheimer’s treatment, donanemab. The FDA intends to convene a last-minute meeting with external advisors to further evaluate the drug’s safety and efficacy in a late-stage trial. This unexpected delay suggests… Continue reading Eli Lilly says FDA delays approval of Alzheimer’s drug in surprise move

Pfizer, amidst a turbulent year marked by the decline of its Covid business, is pivoting its focus towards oncology drugs in a bid to recuperate its financial standing. This strategic shift was underscored during a four-hour investor event, accompanied by a high-profile Super Bowl ad promoting its endeavor to combat cancer. The company, which witnessed… Continue reading Pfizer is betting big on cancer drugs to turn business around after Covid decline – here’s what to know

The Centers for Disease Control and Prevention (CDC) announced two significant Covid recommendations recently, reflecting the ongoing balancing act the agency faces amid the pandemic’s fifth year. Firstly, individuals testing positive for Covid-19 no longer require a minimum five-day isolation period, a contentious change aimed at simplifying guidelines and aligning them with reduced hospitalizations and… Continue reading Healthy Returns: What to know about CDC’s new Covid recommendations

Dexcom announced FDA clearance for its new over-the-counter continuous glucose monitor (CGM) called Stelo, set to be available for purchase online in the summer. CGMs are vital for diabetes management, monitoring glucose levels in real-time through sensors under the skin, sending data to smartphones to alert users and caregivers of emergencies. Stelo, the first glucose… Continue reading Dexcom’s first-ever over-the-counter glucose monitor patch gets FDA clearance

Novo Nordisk’s diabetes drug Ozempic showed promise in treating chronic kidney disease in diabetic patients, according to early results from a large ongoing trial. The drug reduced the risk of kidney disease progression, heart problems, and death by 24% compared to a placebo in patients with both type 2 diabetes and chronic kidney disease. This… Continue reading Novo Nordisk’s diabetes drug Ozempic slashed the risk of kidney disease progression in trial

— Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/430WqL8 It is recommended that investors pre-register and… Continue reading Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024